IDEXX Laboratories stock stays anchored to its diagnostics growth
Published on 07/20/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories (US45168D1046) stock remains anchored to its diagnostics franchise, with the company reporting $3.97 billion in revenue for fiscal 2025 and $1.08 billion in net income, while diluted EPS reached $13.01 for the year. Those figures give investors a clear baseline for the business that sits behind the share price, even when the near-term news flow is limited to routine market context.
Revenue and profit base
The most recent annual figures show how concentrated the company remains on recurring veterinary diagnostics. Fiscal 2025 revenue reached $3.97 billion, up from $3.69 billion in fiscal 2024, while net income rose to $1.08 billion from $972 million a year earlier.
That means revenue increased by $280 million year over year, and net income added $108 million across the same period. Diluted EPS also improved from $11.72 in fiscal 2024 to $13.01 in fiscal 2025, a concrete comparison that shows earnings growth alongside sales growth.
Margins still matter
Profitability stayed high on an absolute basis, and the earnings line remains the clearest lens for the company. The move from $11.72 to $13.01 in diluted EPS is especially relevant because diagnostics businesses are typically judged on repeatable demand and the ability to convert that demand into cash-generating earnings.
For investors, the key question is not whether IDEXX has scale but whether the company can keep turning annual revenue growth into higher earnings per share. Fiscal 2025 already shows that pattern, with both top line and net income finishing above the prior year.
Diagnostics drives the mix
The companys core franchise remains veterinary diagnostics, supported by instruments, consumables, and related software. In annual-report terms, that mix matters because recurring test volumes usually carry more visibility than one-time hardware sales.
That business structure also explains why the annual numbers deserve attention even without a fresh catalyst in the search results: revenue of $3.97 billion, net income of $1.08 billion, and diluted EPS of $13.01 together sketch the operating model that market participants are still pricing.
Stock level and market context
Without a separately sourced live quote in this call, the dated market reference that can be used here is the annual operating base rather than an intraday print. The companys latest annual results still give a useful valuation anchor because they establish the earnings power behind IDEXX Laboratories stock.
As of fiscal 2025, the company had already delivered a clear year over year step-up in revenue, profit, and EPS. That combination usually matters more than headline noise for a diagnostics name with a recurring revenue profile.
Veterinary diagnostics lens
IDEXX Laboratories is best understood through its veterinary diagnostics platform rather than through a single product cycle. That is the business line that ties together the annual figures and explains why repeat testing demand matters to the stock narrative.
When annual revenue reaches $3.97 billion and net income reaches $1.08 billion, the product discussion becomes secondary to the economics of the installed base. The companys diagnostic ecosystem is what makes those results repeatable across fiscal periods.
Annual results set the frame
The stock closes this update around the most recent annual financial frame, not around a new headline event. Fiscal 2025 revenue of $3.97 billion, net income of $1.08 billion, and diluted EPS of $13.01 remain the most concrete evidence for the companys current operating scale.
Those figures also give the cleanest comparison point against fiscal 2024, when revenue was $3.69 billion, net income was $972 million, and diluted EPS was $11.72. For market readers, that year over year improvement is the central fact set behind IDEXX Laboratories stock.
IDEXX Laboratories key facts
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: NASDAQ: IDXX
- Trading venue: NASDAQ
- Sector / Industry: Health Care / Diagnostics and Research
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
